October 2024 summary - Initital focus on the earnings season switched to focus on election outcomes

Monthly comment – October 2024

During October, the focus was initially on the earnings season where financials performed well. However, the high degree of uncertainty surrounding the election in the US increasingly led to heightened market volatility, where both sectors and individual stocks were affected by the polls. There were significant differences in currencies as the dollar strengthened against the euro. Geopolitical tensions continued during the month, however without any major impact on the market. October was a tough month for the healthcare sector, especially for the healthcare services sub-sector.

October was marked by a gradual shift in sentiment. Initially, the US labor market accelerated, supporting a soft landing. The 50 basis point rate cut added fuel to interest-sensitive equities. The stock market seemed little influenced by election outcome speculation, geopolitical turmoil or hurricane Milton. Rather, stronger emphasis was put on third quarter earnings. Here, financials performed well. Inflation largely remained in check, and at month close the market priced in a high probability of a 25 basis point rate cut at the next Fed meeting.

However, as an uncertain US election outcome came in focus, market volatility increased, reflecting a growing risk-off sentiment. Increased caution leading up to an election has been a recurring theme and hardly came as a surprise. Sectors and single stocks were increasingly categorized as winners or losers depending on election outcomes. The same categorization was also seen in healthcare, most notably within hospitals and managed care. The world index and S&P 500 were both down by 2.0 percent and 1.0 percent respectively, measured in US dollars. However, the performance varies significantly depending on investors’ base currency. In October the US dollar strengthened by more than 2 percent against the Euro.

The finish line draws near for the US election

It may take several days to reach an outcome, particularly regarding the division of power between the White House and the two Chambers of Congress. The October polls indicated a somewhat favorable momentum for Trump given an advantage in the swing state Pennsylvania. However, the race remained very close and polling results were well within the margin of error. A similar pattern was also true for the other six swing states likely to sway the result in either candidate’s favor. As for the Senate, the Republicans appeared to have an edge whereas the House remained more uncertain. To add further uncertainty, all the polls struggled with the issue of accurate representation given the low number of survey respondents.

 Geopolitical tensions and focus on internal markets

Stock markets were little impacted by the multiple ongoing major conflicts, apart from the Israel-Iran conflict which posed risks to oil supply that were difficult to fully assess. Deglobalization themes resurfaced, as exemplified by Trump’s campaign to impose significant additional tariffs on goods. Similarly, the EU imposed duties on Chinese electric vehicles. China continued initiatives to revive its national economy with a lessened priority for increased imports.

Relections from the managers

October was a difficult month for the healthcare sector. From our perspective, we saw several events which could be interpreted as negative in the short term. Nevertheless, almost none of these events gave us reason to re-allocate in the portfolio. What seemed to be needed was a correction of expectations, and what we saw was short-term declines, with some expected positive developments being deferred to the future and/or that the risk/reward was seen as being less favorable. This type of situation is especially common during the fall, when the outline for the coming year is becoming clearer and more defined.

High level of political uncertainty

The election of a new US president and the likely shifts in the balance of power in Congress accentuated the sense of uncertainty. The level of political uncertainty is seen as being particularly high in this election. However, we know from history that the perception of risks often becomes magnified at times of elections. Many US election observers are tempted to provide forecasts of the political landscape we will see during the coming four years. However, this is often done without sufficient consideration being given to the fact that presidents do not always get a mandate to run policy which is based entirely on their own political agenda. It is easy for observers to underestimate or even overlook the dependence on the Congress, the many different interest groups within the parties, business stakeholders, trade partners and geopolitical adversaries. In fact, presidents on their own can accomplish relatively little. On top of that, there are only two years until the next (midterm) election.

Important issues that may arise for the incoming president include taxes, tariffs, support to Ukraine, the Mexican border, reshoring of industry/production, as well as the budgeting and detailed regulation of Medicare and Medicaid. Minorities within each party can cause unexpected twists in such budget negotiations.

Many realities will restrict the upcoming power constellation in Washington. The budget is unlikely to become much more expansive without pushing interest rates and thus worsening conditions for the economy. Neither can the US reduce NATOs resources, mandates or budget without diminishing its own geopolitical influence and long-term strategic ability in other parts of the world. This is hardly the ambition of either the Democrats or the Republicans. Major changes in discretionary spending on social programs are likely to be difficult to carry out in the near future since new methods for dimensioning spending supported by both parties would be needed. We therefore believe that there will be an evolution rather than a revolution when it comes to US politics, both when it comes to domestic and foreign policy. In such an environment, the healthcare sector should be able to get some “peace and quiet”, however potential political initiatives could be cause for a degree of uncertainty. As we have mentioned many times before, we live in exciting times and a great deal of surprises can happen. Time will tell.

Andra nyheter från oss

Alla

Direkt

Finwire

Okategoriserat

Rhenman & Partners

Monthly comment (Apr 25): Healthcare sector impacted by political uncertainty

Monthly summary – March 2025: a volatile month, again impacted by the macro-economic and political backdrop

Rhenman Healthcare Equity L/S minskade 13,61 procent i mars – volatilt för hälsovårdssektorn

Monthly summary – February 2025: Sentiment turned sour in February

Rhenman Healthcare Equity L/S sjönk 4,52 procent i februari – politisk osäkerhet pressade marknaden

Rhenman & Partners strengthens its Operations Team

Rhenman & Partners förstärker sitt Operationsteam

Monthly comment – January 2025: All sectors except technology closing in positive territory

Rhenman Healthcare Equity L/S ökade 8,41 procent i januari – stark rotation mot hälsovård

Monthly comment – December 2024

Rhenman Healthcare Equity L/S minskade 10,48 procent i december – tungt avslut på 2024

Monthly summary – November 2024: Once the election results were in, focus shifted torwards likely economic implications

Rhenman Healthcare Equity L/S ökade 1,67 procent i november – volatilt efter valet i USA

How is the healthcare sector affected by the US election results?

Hur påverkas en av världens mest reglerade sektorer av valutgången i USA?

Rhenman Healthcare Equity L/S minskade 2,00 procent i oktober – fokus på rapportperiod och USA-val

Rhenman Healthcare Equity L/S föll 3,53 procent i september – positiv långsiktig utsikt trots volatil marknad

Monthly summary – September 2024

Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners förstärker sitt Investor Relations-team ytterligare

Monthly summary – August 2024

Rhenman Healthcare Equity L/S ökade 3,35 procent i augusti – optimistisk syn på andra halvåret

Rhenman & Partners förstärker investeringsteamet – ytterligare en portföljförvaltare inom biopharma

Rhenman & Partners strengthens investment team – hires additional biopharma PM

Rhenman Healthcare Equity L/S ökade 5,26 procent i juli – tydlig sektorrotation

Monthly update – July 2024

Rhenman Healthcare Equity L/S ökade 1,42 procent i juni – stark månad för aktiemarknaden

Monthly summary – June 2024

Rhenman & Partners celebrates 15 years

Rhenman Healthcare Equity L/S föll 1,29 procent i maj – ser positivt på andra halvåret

Monthly summary – May 2024

Rhenman Healthcare Equity L/S minskade 2,57 procent i april – svag utveckling för de flesta delsektorer

Monthly summary – April

Rhenman Healthcare Equity L/S ökade 5,86 procent i mars – starka bidrag från medicinteknik

Monthly summary – March 2024

Rhenman & Partners strengthens its investor relations team

Rhenman & Partners förstärker Investor Relations

Rhenman Healthcare Equity L/S ökade 4,45 procent i februari – stark månad för bioteknik

Monthly summary – February 2024

Rhenman Healthcare Equity ökade 6,17 procent i januari – Shockwave och Eli Lilly bidrog positivt

Monthly summary – January 2024

Monthly summary – December 2023

Rhenman Healthcare Equity L/S ökade 5,43 procent i december – Cytokinetics bidrog positivt till utvecklingen

Monthly summary – November 2023

Monthly update – November 2023

Rhenman Healthcare Equity ökade 3,58 procent i november – Immunogen bidrog positivt

Monthly summary – October

Rhenman Healthcare Equity minskade 3,03 procent i oktober – två uppköp under månaden

The complex reality of investing in Biopharma

Rhenman Healthcare Equity minskade 6,07 procent i september – Immunovant steg kraftigt efter goda resultat

Monthly summary – September

Rhenman Healthcare Equity ökade 2,91 procent i augusti – Eli Lilly och Novo Nordisk i blickfånget

MONTHLY SUMMARY – AUGUST 2023

Rhenman Healthcare Equity minskade 4,01 procent i juli – Apellis Pharmaceuticals tyngde utvecklingen

Rhenman Healthcare Equity L/S ökade 2,65 procent i juni – ökar allokeringen mot tryggare bolag

Monthly summary – June 2023

Susanna Urdmark lämnar Rhenman & Partners

Susanna Urdmark to leave Rhenman & Partners

Susanna Urdmark lämnar Rhenman & Partners

Rhenman Healthcare Equity ökade 3,24 procent i maj – Immunogen bidrog positivt till utvecklingen

Dan Hoflund ny styrelseledamot för Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S ökade 3,83 procent i april – Tenet Health utvecklades starkt

Monthly summary – April 2023

Rhenman Healthcare Equity L/S minskade 1,02 procent i mars – Novo Nordisk aktiekurs fortsätter stiga

Monthly summary – March 2023

Lars Wedenborn ny styrelseledamot för Rhenman & Partners Asset Management

Lars Wedenborn – ny styrelseledamot Rhenman & Partners Asset Management

Rhenman Healthcare Equity L/S minskade 4,42 procent i februari – rekyl på aktiemarknaderna under februari

Monthly summary – February 2023

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt (uppdatering)

Rhenman Healthcare Equity ökade 3,75 procent i januari – Revance Therapeutics och Tenet Healthcare bidrog positivt

Monthly summary – January 2023

Rhenman Healthcare Equity minskade 4,76 procent i december – Horizon Therapeutics främsta bidragsgivare

Monthly summary – December 2022

Rhenman & Partners strengthens its investment team with a biopharma analyst

Rhenman & Partners förstärker sitt investeringsteam med biopharmananlytiker

Rhenman Healthcare Equity L/S ökade 2,51 procent i november – Abiomed och Horizon Health bidrog positivt

Summary – November 2022

Rhenman Healthcare Equity L/S: +5,7% i oktober, flera faktorer pekar på hyfsad vinter men makrorisker ska ej underskattas – förvaltare

Summary – October 2022

Rhenman Healthcare Equity L/S ökade 5,68 procent i oktober – lyfter fram potentiell presidentcykeleffekt

Rhenman Healthcare Equity L/S: -1,5% i september, investmentbanker sänkte Jazz Pharmaceuticals och Vitrolife (R)

Rhenman Healthcare Equity L/S minskade 1,5 procent i september – Revance Therapeutics och Regeneron Pharmaceuticals främsta bidragsgivare

Teresa Isele ny vd för Rhenman & Partners Asset Management

Teresa Isele ny VD för Rhenman & Partners Asset Management AB

Teresa Isele to be the new CEO of Rhenman & Partners Asset Management AB

Rhenman Healthcare Equity L/S: +1,7% i augusti, förvaltare positiva till amerikansk läkemedelsreform

Rhenman Healthcare Equity L/S ökade 1,70 procent i augusti – biotekniksektorn gynnade utvecklingen

Rhenman Healthcare Equity L/S RC1 SEK: +5,4% i juli, ser på uppgångarna med försiktighet

Rhenman Healthcare Equity L/S ökade 5,39 procent i juli – fortsatt försiktig inställning

Rhenman Healthcare Equity L/S: +4,5% i juni, ser inte läge att öka aktieexponering trots viss ljusning.

Rhenman Healthcare Equity L/S ökade 4,50 procent i juni – stark återhämtning från små- och medelstora bioteknikbolag

Rhenman Healthcare Equity L/S minskade 3,19 procent i maj – stora läkemedelsbolag bidrog positivt

RHENMAN HEALTHCARE EQUITY L/S: -3,2% I MAJ, BUD PÅ BIOHAVEN

Rhenman & Partners fortsätter att expandera – sök rollen som biopharma-analytiker

Rhenman & Partners winner of Refinitiv Lipper Fund Awards Nordics

Rhenman & Partners vinnare av internationellt fondpris

Lediga tjänster inom Investor Relations

Rhenman Healthcare Equity L/S: -4,9% i april, tyngdpunkt på stora bolag för tillfället

Rhenman Healthcare Equity L/S minskade 4,93 procent i april – läkemedelsbolag minst påverkade av ökad global osäkerhet

SV